A practical guide to managing OA: Making sense of current therapies

Presented by Bryan Torres, DVM, PhD, Dipl. ACVS (small animal), Dipl. ACVSMR

Continuing education questionnaire

CE credit: 1

Name

Questions

1. It is estimated that approximately ___% of adult dogs and between __-__% of cats have OA. *
2. A systematic approach to diagnosing OA involves: *
3. When determining an appropriate OA treatment plan for your patient, it is important to consider a multi-modal approach with options from the following categories (represented by the acronym W.E.D.D.S): *
4. Compared to the newpiprant class of NSAIDs (grapiprant), traditional COX modulating NSAIDs like meloxicam (Metacam®) and firocoxib (Previcox®) have more published Evidence Based Medicine supporting their safety and efficacy as a first-line OA therapy. *
5. During the assessment of grapiprant (Galliprant™) efficacy in an induced model of acute arthritis in dogs versus traditional COX-inhibiting NSAIDs such as firocoxib (Previcox®) and carprofen (Rimadyl®), which of the following statements is correct: *
6. The pharmacokinetics/dynamics of Tramadol in the dog make it an excellent stand-alone analgesic in dogs. *
7. When employing a multi-modal approach to the long-term management of OA in dogs, which of the following treatment(s) have studies done in dogs supporting their efficacy as adjunctive treatment: *
8. A recent study examining deracoxib adverse events howed that 55% of dogs with GI perforations had received a __ than approved dose and 60% of dogs with GI perforations received at least 1 other __ or __ within 72 hours of NSAID administration. *
9. When choosing a medication, it is important to consider potential differences in potency variability between branded and generic options, as this may impact treatment consistency. *
10. The long-term use of NSAIDs for the treatment of osteoarthritic pain has been associated with continued improvement and better clinical outcomes. *